Pacific Biosciences is trading 5.8% down at $1.14, amid a broader risk-off session with no clear company-specific announcement identified for August 18, 2026.
- The Nasdaq Composite is down 1.37%, while the S&P 500 is down 0.61%.
- Recent negative sentiment remains linked to the August 5 earnings report, which included a revenue miss, reduced 2026 guidance, and delayed cash-flow breakeven expectations; these developments are not new today.